Primary breast carcinomas with neuroendocrine features: Clinicopathological features and analysis of tumor growth patterns in 36 cases

Talu, Canan Kelten; Leblebıcı, Cem; Öztürk, Tülin; Hacıhasanoğlu, Ezgi; Koca, Sevim Baykal; Güçin, Zühal

doi:10.1016/j.anndiagpath.2018.03.010

Cited by 19 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells range from oval to polygonal or plasmacytoid shape, or also spindled. However, they lack typical nuclear features of NETs, such as salt and pepper chromatin and even monotonous round or oval nuclei, more often displaying irregular appearance or the presence of nucleoli ( 37 ).…”

Section: Pathologymentioning

confidence: 99%

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

et al. 2021

View full text Add to dashboard Cite

Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1% of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain. In the present short review of the medical literature on this topic, we have evaluated in details their epidemiology, risk factors, pathogenesis, pathology, clinical presentation, radiographic aspects, prognosis, and therapy. We have thus been able to identify a number of open issues regarding primary neuroendocrine neoplasms of the breast that need to be clarified. Our ultimate aim was actually to try to understand whether neuroendocrine neoplasms of the breast can be considered a definite clinical entity and if neuroendocrine differentiation of breast tumors has a really clinical relevance.

show abstract

Section: Pathologymentioning

confidence: 99%

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Our outcomes supported that chemotherapy was signi cant improved the survival of NECB patients. For breast carcinoma, received radiation therapy was an important method in improving survival [30]. The survival analysis showed that radiation was ine cient in prolonging the survival.…”

Section: Discussionmentioning

confidence: 99%

Treatment Regimens and Survival Outcomes of Primary Neuroendocrine Carcinoma of Breast Compared with Infiltrating Ductal Carcinoma: A Large Propensity Score Matching Study

Zhou

Zhao

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose The role of treatment regimens in Neuroendocrine carcinoma of breast (NECB) is not well defined. The aim of this study was to explore the clinical characteristics, treatment regimens and prognosis of NECB compared to infiltrating ductal breast carcinomas(IDCB).Method NECB and IDCB patients diagnosed between January 1,2004 and December 12,2016 were enrolled in the researches from the SEER registries. A propensity score matching (PSM) with ratio of 1:5 was performed to correct the selection bias. The Kaplan-Meier curves was used in the analysis of variables. The Cox model was adopted to calculate univariate and multivariate analysis.Results Compared to IDCB, NECB patients were elder white females. The NECB group demonstrated a significantly poorer survival compared to IDCB group in both disease-specific survival (DSS) (p<0.0001) and overall survival (OS) (P<0.0001). In univariate survival analysis, NECB patients were associated with poorer survival compared with IDCB patients. In multivariate survival analysis, earlier T stage, age <60, black race and absence of distant metastasis were independently associated with better DSS and OS after adjusting all variables. In both univariate and multivariate analysis, chemotherapy and surgery were independently associated with better survival. Conclusion NECB were a kind of rare and aggressive breast neoplasm with advanced disease stage and pooper prognosis compared to IDCB. Our outcomes supplied sufficient evidence that surgery and chemotherapy contribute to better survival of NECB patients.

show abstract

“…Cancer cells are predominantly polygonal-oval, sometimes small, with eosinophilic/eosinophilicgranular or clear cytoplasm (Figure 1). The nuclei of tumor cells are mostly round and oval with uniformly distributed or finely granulated chromatin ("salt and pepper") [11]. Finding mucin is known to be tightly related to neuroendocrine differentiation and may be present at variable rates [11].…”

Section: Diagnosismentioning

confidence: 99%

“…Breast cancer cells possess the ability to express neuroendocrine markers and benign neuroendocrine lesions of the breast have never been reported in the literature, unlike other organs, in particular the lung and gastrointestinal tract [7]. NEBC was first described in 1963 by Feyrter and Hartmann [9] and then in 1977, Cubilla and Woodruff reported eight cases of NEBC, providing a histopathological classification and a clinical and prognostic analysis of this subtype of breast cancer [10,11]. In 2003, the WHO defined NEBC as a separate subtype of breast cancer [6].…”

Section: Introductionmentioning

confidence: 99%

Neuroendocrine Cancer of the Breast: A Rare Entity

Irelli

Sirufo

Morelli

et al. 2020

JCM

View full text Add to dashboard Cite

Neuroendocrine breast cancer (NEBC) is a rare histotype of breast carcinoma that presents, in most cases, positive hormone receptors and negative HER2. Indeed, the analysis of gene expression profiles revealed that NEBC belongs mainly to the luminal subtype. Cases of HER2-positive and triple-negative NEBC are rare. The cardinal treatment of early NEBC is surgery, similar to the treatment of invasive non-special histological type carcinoma. The use of radiotherapy follows the criteria applied in infiltrating breast cancer of non-special histotype. In the post-operative phase, therefore after the surgical treatment of mammary quadrantectomy, or mastectomy associated with homolateral sentinel lymph node removal ± axillary dissection, based on the histopathological characteristics of the tumor, the use of chemotherapy (anthracycline + taxane) and/or hormone therapy, whether or not associated with anti-HER2 therapy (trastuzumab) is the rule. Literature data report the use of cisplatin and etoposide, as in small cell lung cancers. Most of the information currently available derive from single case reports or a series of clinical cases; it follows the difficulty of formulating definite recommendations on the correct management of this histological type of breast cancer. This review describes available knowledge on this rare entity to improve the diagnostic and therapeutic strategies and offer insights to stimulate exploration of the many aspects still unknown.

show abstract

Primary breast carcinomas with neuroendocrine features: Clinicopathological features and analysis of tumor growth patterns in 36 cases

Cited by 19 publications

References 35 publications

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

Treatment Regimens and Survival Outcomes of Primary Neuroendocrine Carcinoma of Breast Compared with Infiltrating Ductal Carcinoma: A Large Propensity Score Matching Study

Neuroendocrine Cancer of the Breast: A Rare Entity

Contact Info

Product

Resources

About